Literature DB >> 18070721

Supportive care in multiple myeloma.

Heinz Ludwig1, Niklas Zojer.   

Abstract

In myeloma bone disease, bisphosphonates have been shown to delay the progression of osteolytic lesions and prevent fractures. In the case of painful vertebral fractures, vertebroplasty and kyphoplasty have become standard procedures to control symptoms and restore the original height of the vertebrae. Adequate pain control is of crucial importance for the quality of life of myeloma patients, as is maintaining adequate hemoglobin levels with the use of erythropoietic growth factors. Infections should be treated aggressively in myeloma patients, as these contribute significantly to morbidity and mortality. In patients with repeated infectious complications, prophylactic measures such as long-term application of antibiotic or antiviral medication or use of intravenous immunoglobulins is recommended. The concerted action of these supportive therapies can significantly improve the wellbeing of myeloma patients in phases of disease progression as well as during phases of remission. In progressive disease, certain measures such as adequate pain control and radiotherapy can ameliorate symptoms until the therapeutic effect of systemic anti-neoplastic therapy becomes evident.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18070721     DOI: 10.1016/j.beha.2007.10.001

Source DB:  PubMed          Journal:  Best Pract Res Clin Haematol        ISSN: 1521-6926            Impact factor:   3.020


  9 in total

1.  Maintaining bone health in patients with multiple myeloma: survivorship care plan of the International Myeloma Foundation Nurse Leadership Board.

Authors:  Teresa S Miceli; Kathleen Colson; Beth M Faiman; Kena Miller; Joseph D Tariman
Journal:  Clin J Oncol Nurs       Date:  2011-08       Impact factor: 1.027

Review 2.  International Myeloma Working Group recommendations for global myeloma care.

Authors:  H Ludwig; J S Miguel; M A Dimopoulos; A Palumbo; R Garcia Sanz; R Powles; S Lentzsch; W Ming Chen; J Hou; A Jurczyszyn; K Romeril; R Hajek; E Terpos; K Shimizu; D Joshua; V Hungria; A Rodriguez Morales; D Ben-Yehuda; P Sondergeld; E Zamagni; B Durie
Journal:  Leukemia       Date:  2013-10-09       Impact factor: 11.528

3.  Changes in pain and other symptoms in patients with painful multiple myeloma-related vertebral fracture treated with kyphoplasty or vertebroplasty.

Authors:  Tito R Mendoza; Dhanalakshmi Koyyalagunta; Allen W Burton; Sheeba K Thomas; My-Hanh V Phan; Sergio A Giralt; Jatin J Shah; Charles S Cleeland
Journal:  J Pain       Date:  2012-04-28       Impact factor: 5.820

4.  Bisphosphonate treatment and renal function in 201 myeloma patients undergoing stem cell transplantation.

Authors:  S Schmitt; T Hielscher; C Baldus; K Neben; G Egerer; J Hillengaß; M Raab; D Hose; A D Ho; R Bergner; H Goldschmidt; T M Moehler
Journal:  Int J Hematol       Date:  2013-04-25       Impact factor: 2.490

5.  Infections in Hospitalised Patients with Multiple Myeloma: Main Characteristics and Risk Factors.

Authors:  Toni Valković; Vedrana Gačić; Jelena Ivandić; Božo Petrov; Renata Dobrila-Dintinjana; Elizabeta Dadić-Hero; Antica Načinović-Duletić
Journal:  Turk J Haematol       Date:  2015-09       Impact factor: 1.831

Review 6.  Quality of life and supportive care in multiple myeloma.

Authors:  Melda Cömert; Ajda Ersoy Güneş; Fahri Sahin; Güray Saydam
Journal:  Turk J Haematol       Date:  2013-09-05       Impact factor: 1.831

Review 7.  Immunoglobulin replacement therapy in secondary hypogammaglobulinemia.

Authors:  Nicolò Compagno; Giacomo Malipiero; Francesco Cinetto; Carlo Agostini
Journal:  Front Immunol       Date:  2014-12-08       Impact factor: 7.561

8.  Front line treatment of elderly multiple myeloma in the era of novel agents.

Authors:  Marie-Dominique Venon; Aldo M Roccaro; Julie Gay; Anne-Sophie Moreau; Remy Dulery; Thierry Facon; Irene M Ghobrial; Xavier Leleu
Journal:  Biologics       Date:  2009-07-13

9.  Cost of palliative radiation to the bone for patients with bone metastases secondary to breast or prostate cancer.

Authors:  Gregory Hess; Arie Barlev; Karen Chung; Jerrold W Hill; Eileen Fonseca
Journal:  Radiat Oncol       Date:  2012-10-12       Impact factor: 3.481

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.